SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-020146
Filing Date
2022-05-13
Accepted
2022-05-13 16:41:23
Documents
47
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q inkt-10q_20220331.htm   iXBRL 10-Q 834086
2 EX-31.1 inkt-ex311_8.htm EX-31.1 22057
3 EX-31.2 inkt-ex312_6.htm EX-31.2 22905
4 EX-32.1 inkt-ex321_7.htm EX-32.1 10323
  Complete submission text file 0001564590-22-020146.txt   3194780

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA inkt-20220331.xsd EX-101.SCH 26429
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE inkt-20220331_cal.xml EX-101.CAL 24987
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inkt-20220331_def.xml EX-101.DEF 53818
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE inkt-20220331_lab.xml EX-101.LAB 228789
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inkt-20220331_pre.xml EX-101.PRE 159861
41 EXTRACTED XBRL INSTANCE DOCUMENT inkt-10q_20220331_htm.xml XML 417583
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40908 | Film No.: 22923472
SIC: 2836 Biological Products, (No Diagnostic Substances)